Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Core Viewpoint - Viking Therapeutics, Inc. is set to release its financial results for Q3 2025 on October 22, 2025, and will host a conference call to discuss these results and provide corporate updates [1][2]. Company Overview - Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders [3]. - The company is advancing several clinical programs, including VK2735, a dual agonist targeting GLP-1 and GIP receptors, currently in a Phase 3 obesity program with two trials (VANQUISH-1 and VANQUISH-2) [3]. - VK2735 has shown a favorable safety and tolerability profile in earlier trials, with positive clinical benefits observed [3]. - An oral formulation of VK2735 is also being evaluated in a Phase 2 trial for obesity [3]. - Another key program is VK2809, a selective thyroid hormone receptor beta agonist, which has met primary and secondary endpoints in a Phase 2b study for NASH and fibrosis, and has shown significant reductions in LDL-C and liver fat in a Phase 2a trial for NAFLD [3]. - The company is also developing VK0214 for X-ALD, which has demonstrated safety and significant reductions in VLCFAs in a Phase 1b trial [3].